Abstract: The present invention relates to a pharmaceutical composition for preventing or treating solid cancer and blood cancers such as acute leukemia and chronic leukemia, comprising a derivative compound of 1,2-naphthoquinone or a pharmaceutically acceptable salt thereof as an effective component. The derivative compound of 1,2-naphthoquinone is highly effective in killing cancer cells of various solid cancers, acute leukemia, and chronic leukemia, and thus can be beneficially used as a pharmaceutical composition for preventing or treating cancers, especially solid cancers, acute leukemia, and chronic leukemia.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating solid cancer and blood cancers such as acute leukemia and chronic leukemia, comprising a derivative compound of 1,2-naphthoquinone or a pharmaceutically acceptable salt thereof as an effective component. The derivative compound of 1,2-naphthoquinone is highly effective in killing cancer cells of various solid cancers, acute leukemia, and chronic leukemia, and thus can be beneficially used as a pharmaceutical composition for preventing or treating cancers, especially solid cancers, acute leukemia, and chronic leukemia.

Abstract: Disclosed are a compound represented by Formula (1) below, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3,and Xi to X6 are the same as defined in claim 1.

Abstract: Disclosed is a composition for preventing, ameliorating or treating visceral fat obesity containing a Salvia miltiorrhiza radix extract having excellent activity of reducing visceral fat. Disclosed is a composition for preventing, ameliorating or treating visceral fat obesity containing an extract of Salvia miltiorrhiza radix that has efficacy specific for visceral fat when administered to obese model animal mice that have obesity caused by decreased leptin secretion and diet-induced obesity (DIO) mice in which obesity is induced using a high-fat diet. Disclosed is a composition for preventing, ameliorating or treating visceral fat obesity containing an S. miltiorrhiza extract, wherein the S. miltiorrhiza extract inhibits the production of triglyceride (TG) in liver tissue and the blood, indicating that the S. miltiorrhiza extract has inhibitory activity on visceral-fat-type obesity, and the S.